Guidelines for investigating causality of sequence variants in human disease
By D. MacArthur, T. Manolio, D. Dimmock, H. Rehm, Jay Shendure, Gonçalo R. Abecasis, D. Adams, Russ B. Altman, Stylianos E. Antonarakis, Euan A. Ashley and 17 more. 2014
1,235 citations recorded by the source corpus.
The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human genome are urgently needed. Without rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight several areas that require further resource development.
Subfields: Cancer Research, Genetics, Causal Inference & Discovery, Computational Biology & Bioinformatics
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
- Kai-Uwe Eckardt
- Isaac S. Kohane
- Mark Yandell
- Karen Eilbeck
- Karl V. Voelkerding
- Jessica Alföldi
- Computational Pan-Genomics Consortium
- Aaron R. Quinlan
In Computational Biology & Bioinformatics
- Mark Yandell
- Karen Eilbeck
- Jessica Alföldi
- UniProt Consortium
- Computational Pan-Genomics Consortium
- Aaron R. Quinlan
- Beryl B. Cummings
- J. Kosmicki
Citations in the corpus
- UniProt: the universal protein knowledgebase (2016, background): “With the increasing interest and progress in genomic-based medicine understanding the effects of variation on protein function is a key component of gene and variant curation (26,27).”
- Quantitative missense variant effect prediction using large-scale mutagenesis data (2017, neutral): “However, in both laboratory and clinical settings, determining the impact of a missense variant on a protein’s function remains a challenge (MacArthur et al., 2014).”
- Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (2015, background): “Thus, it is recommended that both terms be replaced by the term “variant” with the following modifiers: (1) pathogenic, (2) likely pathogenic, (3) uncertain significance, (4) likely benign, or (5) benign.”
- Computational pan-genomics: status, promises and challenges (2016, background): “Yet, caution is warranted because any genome sequence may contain many potentially functional, rare variants that could result in false-positive claims about disease-causing variants [55].”
- Comprehensive Analysis of Tissue-wide Gene Expression and Phenotype Data Reveals Tissues Affected in Rare Genetic Disorders (2017, background): “, affected tissues, remains a challenge (MacArthur et al., 2014).”
- InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. (2017, background): “, that a portion of benign variants are incorrectly classified as pathogenic variants.(48,49) For example, Dorschner et al.”
- Improving genetic diagnosis in Mendelian disease with transcriptome sequencing (2016, neutral): “The primary challenge of these genome-based diagnostics is that the capacity of WES and WGS to discover genetic variants substantially exceeds our ability to interpret their functional and clinical impact (5-7).”
- Transcript expression-aware annotation improves rare variant discovery and interpretation (2019, background): “transcript structure and/or a CDS that conflicted with updated GENCODE annotation criteria (these annotations had been or will be changed in future GENCODE releases based on this evaluation); (2) ‘putative’, where the model structure and CDS satisfied our current annotation criteria, although we jud”
- OncoKB: A Precision Oncology Knowledge Base (2017, background): “While multiple classification systems exist for the annotation of germline variants 60,61 , efforts to define the clinical utility of somatic alterations have been limited to established biomarkers 62–64 and prior efforts have often classified actionability as a binary variable resulting in the…”
- Integrated genome and transcriptome sequencing identifies a noncoding mutation in the genome replication factor DONSON as the cause of microcephaly-micromelia syndrome (2017, background): “In contrast, noncoding variants are harder to interpret due to the lack of a functional understanding of most noncoding elements in the genome (Pagani and Baralle 2004; MacArthur et al. 2014).”
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. (2017, background): “Although challenging, this is necessary to focus on translation of the most promising findings.(190,191) An example is the original discovery of the APOL1”